Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Survival modeling" patented technology

Auxiliary assessment method for prognosis of nasopharynx cancer based on enhanced MRI radiomics

The invention relates to an auxiliary assessment method for prognosis of nasopharynx cancer based on enhanced MRI radiomics. The auxiliary assessment method comprises the steps of: (1), performing MRIimage processing; (2), extracting imaging features; (3), screening the imaging features; (4), establishing a radiomics scoring formula; (5), screening clinical risk factors; and (6), establishing a prognostic survival model: establishing a prognostic observation model through combination of a radiomics score and the clinical risk factors of a patient with nasopharynx cancer, performing qualitative and quantitative prediction on the PFS (progression free survival) of the patient, and furthermore, assessing the performance of the prognostic survival model. The auxiliary assessment method in theinvention has little harm to the image examination of the patient; qualitative and quantitative analysis on the survival time of a specific patient is carried out; therefore, a doctor is assisted tomake an individualized treatment and follow-up visit scheme; furthermore, the doctor is assisted to assess the survival and recurrence time of the patient; simultaneously, the performance of the obtained prognostic survival model is verified; and thus, the accuracy of a prognostic prediction model is ensured.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Combined marker for predicting prognosis of liver cancer and application of combined marker

The invention discloses a group of combined markers for predicting liver cancer prognosis and application thereof, and belongs to the technical field of biological medicines. Liver cancer is one of the most common cancer-related death reasons in the world and is extremely poor in prognosis, and recognition of effective prognosis biomarkers of liver cancer has important clinical significance. The invention provides a model for prognosis determination and risk assessment of a liver cancer patient based on combined biomarkers. The related combined biomarkers comprise CDCA3, CDCA8, SSRP1, HN1 and KIF4A. The prognosis risk score is quantitatively calculated according to the expression condition of the combined biomarker in a case sample, the patient is divided into a high-risk group and a low-risk group according to the median value of the risk score of the patient, and the result shows that the prognosis of the patient in the low-risk group is obviously superior to that of the patient in the high-risk group; and the accuracy and specificity of the prognosis survival model are verified through a K-Mplot survival curve, an ROC curve and the survival time and state of the patient. Therefore, the prediction model is of great significance to prognosis prediction and targeted therapy of patients with liver cancer.
Owner:QINGDAO MUNICIPAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products